These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4329636)

  • 1. Investigation of type 3 poliovirus variants with increased L-cystine-dependence as live vaccines.
    Elbert LB; Chumakov MP; Krutyanskaya GL; Ralph NM; Tyufanov AV; Sokolova IS; Alpatova GA
    Arch Gesamte Virusforsch; 1971; 33(3):259-70. PubMed ID: 4329636
    [No Abstract]   [Full Text] [Related]  

  • 2. A new type 3 attenuated poliovirus for possible use in oral poliovirus vaccine.
    Vonka V; Janda Z; Simon J; Adam E; Stárek M
    Prog Med Virol; 1967; 9():204-55. PubMed ID: 4293687
    [No Abstract]   [Full Text] [Related]  

  • 3. Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use, with special reference to type 3 poliovirus.
    Bull World Health Organ; 1969; 40(6):925-45. PubMed ID: 4310724
    [No Abstract]   [Full Text] [Related]  

  • 4. Studies on characteristics of poliovirus. 3. Investigation of d, rct, h and n markers of poliovirus isolated after vaccination with the Type 1, Chat strain.
    Böttiger M
    Arch Gesamte Virusforsch; 1966; 18(2):135-54. PubMed ID: 4293025
    [No Abstract]   [Full Text] [Related]  

  • 5. Neutralizing capacity of poliovirus type 3 antibodies tested against 5 different intratypic variants of poliovirus type 3. A comparative study in children immunized with live, inactivated, or both types of poliovirus vaccines.
    Böttiger M
    Arch Gesamte Virusforsch; 1971; 35(2):251-5. PubMed ID: 4332939
    [No Abstract]   [Full Text] [Related]  

  • 6. [Studies of genetic markers of poliovirus strains].
    Yamawaki S
    Kumamoto Igakkai Zasshi; 1970 Dec; 44(12):1165-208. PubMed ID: 4325315
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of antibody responses and virus shedding following administration of trivalent oral poliomyelitis vaccines prepared either in monkey or human diploid cell substrates.
    Freestone DS; Kelly A; Ferris R; Simmons RL; Bowker C; Letley E; Bye C
    J Hyg (Lond); 1980 Feb; 84(1):17-28. PubMed ID: 6243327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative monkey neurovirulence of Sabin type III poliovirus vaccines.
    Boulger LR; Marsden SA; Magrath DI; Taffs LF; Schild GC
    J Biol Stand; 1979 Apr; 7(2):97-111. PubMed ID: 225329
    [No Abstract]   [Full Text] [Related]  

  • 9. Investigation of some possibilities of producing type 3 vaccine poliovirus with greater genetic stability. I. Preliminary experiments with passage variants.
    Elbert LB; Chumakov MP; Krutyanskaya GL; Ralph NM; Tyufanov AV
    Acta Virol; 1968 May; 12(3):193-202. PubMed ID: 4385148
    [No Abstract]   [Full Text] [Related]  

  • 10. GENETIC MARKERS OF POLIOVIRUS STRAINS ISOLATED FROM PARALYTIC PATIENTS PRIOR TO AND AFTER SABIN VACCINATION PROGRAMS. I. STUDIES ON TYPE 1 STRAINS.
    FURESZ J; ARMSTRONG RE; YAROSH W; NAGLER FP
    Am J Hyg; 1964 Jul; 80():45-54. PubMed ID: 14192769
    [No Abstract]   [Full Text] [Related]  

  • 11. GENETIC MARKERS OF POLIOVIRUS STRAINS ISOLATED FROM PARALYTIC PATIENTS PRIOR TO AND AFTER SABIN VACCINATION PROGRAMS. II. STUDIES ON TYPE 3 STRAINS.
    FURESZ J; ARMSTRONG RE; MOREAU P; NAGLER FP
    Am J Hyg; 1964 Jul; 80():55-61. PubMed ID: 14192770
    [No Abstract]   [Full Text] [Related]  

  • 12. Neurovirulence of polioviruses isolated from sewage and stool of healthy children. I. Studies on neurovirulence, antigenic marker and RCT-40 mrker of type 2 strains.
    Wilterdink JB; Smit GL; Verlinde JD
    Arch Gesamte Virusforsch; 1969; 28(1):68-76. PubMed ID: 4315814
    [No Abstract]   [Full Text] [Related]  

  • 13. Diplovax. A new oral polio vaccine.
    Med Lett Drugs Ther; 1972 Aug; 14(16):57-8. PubMed ID: 4346222
    [No Abstract]   [Full Text] [Related]  

  • 14. Poliovirus vaccine and vaccine-derived polioviruses.
    Plotkin SA
    N Engl J Med; 2010 Nov; 363(19):1870; author reply 1870-1. PubMed ID: 21047242
    [No Abstract]   [Full Text] [Related]  

  • 15. MARKER TEST OF POLIOVIRUS IN RELATION TO MASS VACCINATION WITH LIVE ORAL VACCINES.
    TOYOSHIMA K; MITSUDA B; TADOKORO J; YAMADA T; KUNITA N
    Biken J; 1963 Jul; 6():57-72. PubMed ID: 14147706
    [No Abstract]   [Full Text] [Related]  

  • 16. [ON THE NEUROVIRULENCE TEST OF LIVE POLIOVIRUS VACCINES. I. BASES, TECHNIC AND EVALUATION OF THE RESEARCH ON NEUROVIRULENCE MEASUREMENT IN MONKEYS].
    BONIN O; UNTERHARNSCHEIDT F
    Arch Psychiatr Nervenkr; 1964 Nov; 206():260-71. PubMed ID: 14344120
    [No Abstract]   [Full Text] [Related]  

  • 17. [Findings on the success of vaccination and revaccination with live and inactivated vaccines against poliomyelitis].
    Dostal V; Haenzel I; Sturm W
    Schweiz Med Wochenschr; 1969 Sep; 99(37):1322-4. PubMed ID: 4309326
    [No Abstract]   [Full Text] [Related]  

  • 18. [Studies of the effect poliomyelitis live vaccine (Sabin) in small infants].
    Hussels H; Hennessen W
    Med Klin; 1966 Feb; 61(5):165-7. PubMed ID: 4293160
    [No Abstract]   [Full Text] [Related]  

  • 19. [Excretion rates after Sabin oral vaccination against poliomyelitis in Tyrol].
    Bauer P
    Arch Hyg Bakteriol; 1968 Dec; 152(5):410-4. PubMed ID: 4313799
    [No Abstract]   [Full Text] [Related]  

  • 20. Enterovirus surveillance following a community-wide oral poliovirus vaccination program: a seven-year study.
    Horstmann DM; Emmons J; Gimpel L; Subrahmanyan T; Riordan JT
    Am J Epidemiol; 1973 Mar; 97(3):173-86. PubMed ID: 4348244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.